Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once - daily or potentially once-weekly oral dosing. - ASC50 had...
Dubai advances position as Middle East, Africa and South Asia's leading global financial centre
DUBAI, UAE, Oct. 20, 2025 /PRNewswire/ -- Dubai continues to advance its position as the Middle East, Africa and South Asia's (MEASA) leading global financial centre. DIFC The announcement coincides with DIFC surpassing 8,000 active registered...
Recharge Reports Record 39% Sales Growth in 2024 and have made a Strategic Leap Into B2B
Total sales up 39% to €695 million Net revenue up 32% to €73.6 million EBITDA doubling to €8.1 million and net profit reaching €7.5 million Secured €45 million acquisition financing facility from ABN AMRO Entered 2025 with the acquisition of...
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December...